Sound Shore Management Inc. CT decreased its position in shares of Allergan PLC. (NYSE:AGN) by 0.8% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 698,448 shares of the company’s stock after selling 5,956 shares during the period. Allergan PLC. accounts for 2.8% of Sound Shore Management Inc. CT’s portfolio, making the stock its 19th largest position. Sound Shore Management Inc. CT’s holdings in Allergan PLC. were worth $166,873,000 at the end of the most recent reporting period.
Other large investors have also bought and sold shares of the company. Crestwood Advisors Group LLC acquired a new stake in Allergan PLC. during the first quarter worth approximately $103,000. Sunbelt Securities Inc. acquired a new stake in Allergan PLC. during the fourth quarter worth approximately $107,000. Feltz Wealth PLAN Inc. acquired a new stake in Allergan PLC. during the first quarter worth approximately $107,000. Enterprise Financial Services Corp boosted its stake in Allergan PLC. by 62.7% in the first quarter. Enterprise Financial Services Corp now owns 462 shares of the company’s stock worth $110,000 after buying an additional 178 shares during the period. Finally, Webster Bank N. A. boosted its stake in Allergan PLC. by 31.0% in the first quarter. Webster Bank N. A. now owns 520 shares of the company’s stock worth $124,000 after buying an additional 123 shares during the period. Hedge funds and other institutional investors own 84.63% of the company’s stock.
Allergan PLC. (NYSE:AGN) opened at 235.49 on Monday. The stock has a market capitalization of $79.09 billion, a price-to-earnings ratio of 7.34 and a beta of 1.16. The firm has a 50-day moving average of $230.75 and a 200-day moving average of $226.62. Allergan PLC. has a 1-year low of $184.50 and a 1-year high of $261.27.
Allergan PLC. (NYSE:AGN) last released its quarterly earnings results on Tuesday, May 9th. The company reported $3.35 EPS for the quarter, beating the consensus estimate of $3.32 by $0.03. The business had revenue of $3.57 billion for the quarter, compared to analyst estimates of $3.53 billion. Allergan PLC. had a net margin of 82.42% and a return on equity of 7.29%. The company’s quarterly revenue was up 5.1% on a year-over-year basis. During the same period in the prior year, the business earned $3.04 earnings per share. Equities research analysts anticipate that Allergan PLC. will post $16.08 EPS for the current year.
The firm also recently declared a quarterly dividend, which was paid on Thursday, June 15th. Stockholders of record on Thursday, May 18th were given a $0.70 dividend. The ex-dividend date of this dividend was Tuesday, May 16th. This represents a $2.80 annualized dividend and a dividend yield of 1.19%. Allergan PLC.’s dividend payout ratio is presently 9.63%.
A number of research firms have recently commented on AGN. Deutsche Bank AG raised their target price on Allergan PLC. from $262.00 to $265.00 and gave the company a “buy” rating in a research report on Tuesday, March 28th. Royal Bank Of Canada restated a “buy” rating and set a $279.00 target price on shares of Allergan PLC. in a research report on Tuesday, March 14th. Mizuho dropped their target price on Allergan PLC. from $275.00 to $267.00 and set a “buy” rating on the stock in a research report on Friday, June 9th. BidaskClub upgraded Allergan PLC. from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, ValuEngine cut Allergan PLC. from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Nine research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Allergan PLC. presently has a consensus rating of “Buy” and a consensus price target of $270.91.
In other news, Director Nesli Basgoz sold 1,889 shares of the stock in a transaction that occurred on Thursday, May 18th. The shares were sold at an average price of $220.45, for a total value of $416,430.05. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 0.36% of the stock is owned by corporate insiders.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.